Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Signs Companion Diagnostic Agreement with Hengrui Therapeutics Inc

08/18/2020 | 09:54am EDT

Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Hengrui Therapeutics, Inc. (HTI), a U.S. subsidiary of Chinese pharmaceutical company Jiangsu Hengrui Medicine Co., Ltd. (JHM), to develop a CDx that will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System.

Once commercialized, the CDx will be used to identify non-small cell lung cancer (NSCLC) patients who may be eligible for pyrotinib, JHM's novel, irreversible pan-HER2 tyrosine kinase inhibitor.

HER2 mutations are present in about 4 percent of patients with NSCLC, yet there is currently no targeted therapy approved by the U.S. Food & Drug Administration (FDA) for patients with HER2-mutated NSCLC.1 HTI recently released results from a phase 2 clinical trial demonstrating that pyrotinib showed promising antitumor activity in patients with HER2-mutant advanced NSCLC who were previously treated with chemotherapy. The drug received conditional approval in China for the treatment of HER2-positive, advanced or metastatic breast cancer in chemotherapy-treated patients in 2018 based on positive phase 2 clinical trial results and full approval in 2020 based on two successful phase 3 studies. HTI's global clinical trial program for pyrotinib is currently in phase 3 clinical trials, with studies underway in China, Europe and the United States.

'An approved targeted therapy for patients with HER2-mutated non-small cell lung cancer could save thousands of lives,' said Dr. Lianshan Zhang, R&D president of JHM. 'We are excited to partner with Thermo Fisher on a companion diagnostic that will make it easier for clinicians to identify patients who may benefit from pyrotinib, helping us broaden participation in clinical trials and make precision medicine available for more patients.'

Under the terms of the agreement, Thermo Fisher will retain rights to commercialize the test globally and will seek approval from regulatory agencies. The company has previously announced a CDx agreement that also leverages the Oncomine Precision Assay for the Genexus System. In June the FDA granted the assay Breakthrough Device Designation to identify isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations in low-grade glioma patients.

'We are seeing strong demand from our pharmaceutical partners for our NGS solutions,' said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. 'The Oncomine Precision Assay for the Genexus System is designed to comply with evolving regulations, such as those currently in development in China and Europe. It can be deployed to prospectively test and enroll clinical trial participants as well as for retrospective analysis of local laboratory tests used for clinical trial enrollment. It is the ideal solution to support trial programs on a global scale.'

The Oncomine Precision Assay can detect more than 50 cancer-related biomarkers from formalin-fixed paraffin-embedded (FFPE) tumor tissues or liquid biopsy specimens. It is designed to run on the Genexus System, a first-of-its-kind NGS platform that features an automated workflow with a one-day turnaround time and the lowest sample requirements on the market for detection of both DNA and RNA variants. Currently, the integrated sequencer and assay are labeled for research use only.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Contact:

Mauricio Minotta

Tel: 760-805-5266

Email: mauricio.minotta@thermofisher.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
JIANGSU HENGRUI MEDICINE CO., LTD. 0.94% 46.15 End-of-day quote.-50.31%
THERMO FISHER SCIENTIFIC -0.38% 560.85 Delayed Quote.20.74%
All news about THERMO FISHER SCIENTIFIC
10:12aTHERMO FISHER SCIENTIFIC : FDA Approves Tissue-Based NGS Companion Diagnostic fo..
AQ
08:12aTHERMO FISHER SCIENTIFIC : Automated Enzyme Analyzers Streamline Enzyme Assay Ap..
PU
03:00aThermo Fisher Scientific Announces CE-IVD Mark for Next-Generation TaqPath CO..
CI
09/15TAKEDA PHARMACEUTICAL : Exkivity Wins FDA Approval for Treatment of Lung Cancer ..
MT
09/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
09/13THERMO FISHER SCIENTIFIC : - Oncomine Dx Target Test Receives MHLW Approval as a..
AQ
09/10Thermo Fisher Scientific Inc. Receives Japan Ministry of Health, Labour and W..
CI
09/09THERMO FISHER SCIENTIFIC : to Host Virtual Investor Day
PR
09/08Thermo Scientific TSQ Plus Triple Quadrupole Mass Spectrometer Portfolio Meet..
CI
09/08Thermo Fisher Scientific Inc. to Further Expand Global Network of Single-Use ..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 36 059 M - -
Net income 2021 7 164 M - -
Net Debt 2021 13 534 M - -
P/E ratio 2021 31,3x
Yield 2021 0,17%
Capitalization 221 B 221 B -
EV / Sales 2021 6,52x
EV / Sales 2022 6,67x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 562,96 $
Average target price 580,31 $
Spread / Average Target 3,08%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC20.74%221 479
DANAHER CORPORATION45.89%232 203
INTUITIVE SURGICAL, INC.27.80%124 407
SIEMENS HEALTHINEERS AG35.78%75 605
EDWARDS LIFESCIENCES CORPORATION32.57%75 435
ILLUMINA, INC.21.59%65 997